Review





Similar Products

mouse nov ccn3 duoset elisa  (R&D Systems)
93
R&D Systems mouse nov ccn3 duoset elisa
Mouse Nov Ccn3 Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccn3/Mouse+NOV%2FCCN3+DuoSet+ELISA/pmc12556222-62-0-5
Average 93 stars, based on 1 article reviews
mouse nov ccn3 duoset elisa - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
recombinant mouse ccn3 protein  (R&D Systems)
93
R&D Systems recombinant mouse ccn3 protein
Recombinant Mouse Ccn3 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccn3/Recombinant+Mouse+NOV%2FCCN3+Protein%2C+CF/pmc12578405__jci-135-190635-s212-66-5-9
Average 93 stars, based on 1 article reviews
recombinant mouse ccn3 protein - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
ccn3 antobody santa cruz biotechnology sc 136967 wb wb  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology ccn3 antobody santa cruz biotechnology sc 136967 wb wb
Ccn3 Antobody Santa Cruz Biotechnology Sc 136967 Wb Wb, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccn3/nov+Antibody/pm41109656-420-31-33
Average 93 stars, based on 1 article reviews
ccn3 antobody santa cruz biotechnology sc 136967 wb wb - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
recombinant human ccn3 protein 1640 nv  (R&D Systems)
93
R&D Systems recombinant human ccn3 protein 1640 nv
Recombinant Human Ccn3 Protein 1640 Nv, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccn3/Recombinant+Human+NOV%2FCCN3+Protein%2C+CF/pm41109656-71-0-8
Average 93 stars, based on 1 article reviews
recombinant human ccn3 protein 1640 nv - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
antibodies against ccn3  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc antibodies against ccn3
Antibodies Against Ccn3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccn3/CCN3+Antibody/pm41096895-177-35-48
Average 93 stars, based on 1 article reviews
antibodies against ccn3 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
fulllength ccn3 complementary dna  (GenScript corporation)
90
GenScript corporation fulllength ccn3 complementary dna
Fulllength Ccn3 Complementary Dna, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccn3/plasmid+encoding+ccn3/pm40156746-49-1-13
Average 90 stars, based on 1 article reviews
fulllength ccn3 complementary dna - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
human upar elisa kits  (R&D Systems)
93
R&D Systems human upar elisa kits
The <t>ELISA</t> results of the comparative analysis of Nov levels between controls, benign laryngeal lesions and laryngeal squamous cell carcinoma (LSCC). (A) Prior to surgery, there was a significant overexpression in both the benign and tumor groups compared to the control group. (B) However, no differences were found when comparing pre and postoperative samples (1–3 months after surgery) within the benign and tumor groups. (C) The presentation of individual patients with benign lesions thin the benign and tumor groups before and after surgery serves to illustrate the course of Nov serum levels. ns = not significant, *** p < 0.001, **** p < 0.0001.
Human Upar Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccn3/Human+NOV%2FCCN3+DuoSet+ELISA/pmc12076192-209-10-16
Average 93 stars, based on 1 article reviews
human upar elisa kits - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
duoset human nov ccn3  (R&D Systems)
93
R&D Systems duoset human nov ccn3
The <t>ELISA</t> results of the comparative analysis of Nov levels between controls, benign laryngeal lesions and laryngeal squamous cell carcinoma (LSCC). (A) Prior to surgery, there was a significant overexpression in both the benign and tumor groups compared to the control group. (B) However, no differences were found when comparing pre and postoperative samples (1–3 months after surgery) within the benign and tumor groups. (C) The presentation of individual patients with benign lesions thin the benign and tumor groups before and after surgery serves to illustrate the course of Nov serum levels. ns = not significant, *** p < 0.001, **** p < 0.0001.
Duoset Human Nov Ccn3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccn3/Human+NOV%2FCCN3+DuoSet+ELISA/pmc12076192-209-6-16
Average 93 stars, based on 1 article reviews
duoset human nov ccn3 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


The ELISA results of the comparative analysis of Nov levels between controls, benign laryngeal lesions and laryngeal squamous cell carcinoma (LSCC). (A) Prior to surgery, there was a significant overexpression in both the benign and tumor groups compared to the control group. (B) However, no differences were found when comparing pre and postoperative samples (1–3 months after surgery) within the benign and tumor groups. (C) The presentation of individual patients with benign lesions thin the benign and tumor groups before and after surgery serves to illustrate the course of Nov serum levels. ns = not significant, *** p < 0.001, **** p < 0.0001.

Journal: Cancer Medicine

Article Title: Early Detection and Longitudinal Follow‐Up of Non‐Invasive Biomarkers for Laryngeal Squamous Cell Carcinoma: First Results of the BEAL ‐Study

doi: 10.1002/cam4.70961

Figure Lengend Snippet: The ELISA results of the comparative analysis of Nov levels between controls, benign laryngeal lesions and laryngeal squamous cell carcinoma (LSCC). (A) Prior to surgery, there was a significant overexpression in both the benign and tumor groups compared to the control group. (B) However, no differences were found when comparing pre and postoperative samples (1–3 months after surgery) within the benign and tumor groups. (C) The presentation of individual patients with benign lesions thin the benign and tumor groups before and after surgery serves to illustrate the course of Nov serum levels. ns = not significant, *** p < 0.001, **** p < 0.0001.

Article Snippet: The assays were performed using the DuoSet human Nov/CCN3 and human uPAR ELISA kits (DY1640, DY807 R&D Systems Inc., Minneapolis, MN).

Techniques: Enzyme-linked Immunosorbent Assay, Over Expression, Control

The immunohistochemical staining of the biomarkers Nov and uPAR in laryngeal squamous cell carcinoma (LSCC) samples compared to control tissue indicates a significant overexpression of both markers in epithelial tumor tissue. A 50 μm scale is provided in the upper left corner of each image.

Journal: Cancer Medicine

Article Title: Early Detection and Longitudinal Follow‐Up of Non‐Invasive Biomarkers for Laryngeal Squamous Cell Carcinoma: First Results of the BEAL ‐Study

doi: 10.1002/cam4.70961

Figure Lengend Snippet: The immunohistochemical staining of the biomarkers Nov and uPAR in laryngeal squamous cell carcinoma (LSCC) samples compared to control tissue indicates a significant overexpression of both markers in epithelial tumor tissue. A 50 μm scale is provided in the upper left corner of each image.

Article Snippet: The assays were performed using the DuoSet human Nov/CCN3 and human uPAR ELISA kits (DY1640, DY807 R&D Systems Inc., Minneapolis, MN).

Techniques: Immunohistochemical staining, Staining, Control, Over Expression

The ELISA results of the comparative analysis of uPAR levels between controls, benign laryngeal lesions and laryngeal squamous cell carcinoma (LSCC). (A) Preoperatively, both benign and tumor groups exhibited significant overexpression compared to the control group. (B) In the follow‐up period of 1–3 months, the uPAR concentration in the benign group decreased significantly compared to the preoperative state, while no changes were observed in the tumor group. (C) The presentation of individual patients with benign lesions before and after surgery underlines the decrease in uPAR serum levels after surgery. ns = not significant, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: Cancer Medicine

Article Title: Early Detection and Longitudinal Follow‐Up of Non‐Invasive Biomarkers for Laryngeal Squamous Cell Carcinoma: First Results of the BEAL ‐Study

doi: 10.1002/cam4.70961

Figure Lengend Snippet: The ELISA results of the comparative analysis of uPAR levels between controls, benign laryngeal lesions and laryngeal squamous cell carcinoma (LSCC). (A) Preoperatively, both benign and tumor groups exhibited significant overexpression compared to the control group. (B) In the follow‐up period of 1–3 months, the uPAR concentration in the benign group decreased significantly compared to the preoperative state, while no changes were observed in the tumor group. (C) The presentation of individual patients with benign lesions before and after surgery underlines the decrease in uPAR serum levels after surgery. ns = not significant, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The assays were performed using the DuoSet human Nov/CCN3 and human uPAR ELISA kits (DY1640, DY807 R&D Systems Inc., Minneapolis, MN).

Techniques: Enzyme-linked Immunosorbent Assay, Over Expression, Control, Concentration Assay

(A) The receiver operating chrarcteristic (ROC) curve illustrates the results for Nov. The area under the curve is 0.8641, with a cut‐off value set at a sensitivity of 0.796 and a specificity of 0.86. (B) The ROC curve shows the biomarker uPAR. The area under the curve is 0.9775, with a cut‐off value of uPAR exhibiting a sensitivity of 0.958 and a specificity of 0.92.

Journal: Cancer Medicine

Article Title: Early Detection and Longitudinal Follow‐Up of Non‐Invasive Biomarkers for Laryngeal Squamous Cell Carcinoma: First Results of the BEAL ‐Study

doi: 10.1002/cam4.70961

Figure Lengend Snippet: (A) The receiver operating chrarcteristic (ROC) curve illustrates the results for Nov. The area under the curve is 0.8641, with a cut‐off value set at a sensitivity of 0.796 and a specificity of 0.86. (B) The ROC curve shows the biomarker uPAR. The area under the curve is 0.9775, with a cut‐off value of uPAR exhibiting a sensitivity of 0.958 and a specificity of 0.92.

Article Snippet: The assays were performed using the DuoSet human Nov/CCN3 and human uPAR ELISA kits (DY1640, DY807 R&D Systems Inc., Minneapolis, MN).

Techniques: Biomarker Discovery